Author (year)	Country, PCOS recruitment source	Control recruitment source	Control description	Measurement of height, weight, waist, and/or waist– hip ratio	Diet and physical activity	Medications
			Studies from Updated System	atic Review		
Aarestrup et al. (2021)	Denmark; discharge diagnoses obtained by linked to the Danish National Patient Registry	Copenhagen School Health Records Registry	All children who attended a public or private school in Copenhagen			
Altinkaya <i>et al.</i> 2014)	Turkey; not stated	Not stated	Age-matched women who had regular menses and no clinical or biochemical hyperandrogenism or PCO		No diet change within last 3 months	No subject has been on hormonal contraceptives or other medica- tions for three months prior to the study
Ates <i>et al.</i> (2018)	Turkey; Department of Gynaecology and Obstetrics at University	Same group as PCOS	Age-matched adolescent girls with regular menstrual cycles, normal ovaries on ultrasonography and the absence of symptoms of hyperandrogenism who were ad- mitted to the clinic for other gynaecologic disorders	WC was measured as the smallest circumference at the level of the umbilicus and hip circumference was measured at the levels of the major trochanters through the pu- bic symphysis		
Ayonrinde e <i>t al.</i> (2016)	Australia; Western Australian Pregnancy Cohort	Same group as PCOS				
3ehboudi- Gandevani et <i>al.</i> 2017)	Iran; Outpatient Endocrinology Unit	Not stated	Healthy eumenorrhoeic non-hir- sute women aged 20–40 years	The waist circumference (WC) was measured between the lower rib margin and the iliac crest at the end of a normal expiration. The hip circumference (HC) was mea- sured at the levels of buttocks' maximum extension		Without any medication that in- terfered with the normal function of the hypothalamic-pituitary-go- nadal axis such as hormones, glu- cocorticoids, insulin sensitizers, and anti-androgen therapies
3oyle et <i>al.</i> (2015)	Australia; Darwin Region Urban Indigenous Diabetes study partici- pants—living in defined geographi- cal region within Darwin area, Australia, for ≥6 months	Same group as PCOS	Non-hyperandrogenic or hyperan- dogenic or idiopathic hirsutism			
Larmina <i>et al.</i> 2019)	Italy; Department of Health Sciences at University	Same group as Control	Normal ovulatory women were selected as controls. These women were drawn from the same population base, had no complaints related to androgen excess and were matched for age with our patient population of women with PCOS			No patient had received any medi- cation for at least 3 months before the study
Christensen et al. 2013)	USA; subset of patients enrolled in large population-based cohort study, KPSC Children's Health Study 2007–2009. This actively enrolled children in a large, pre- paid integrated managed health- care system	Same group as PCOS	No indication of NIH criteria			

Human Reproduction, pp. 1-9, 2023 https://doi.org/10.1093/humrep/dead053

human reproduction

SUPPLEMENTARY DATA

(continued)

Author (year)	Country, PCOS recruitment source	Control recruitment source	Control description	Measurement of height, weight, waist, and/or waist– hip ratio	Diet and physical activity	Medications
Çınar et <i>al.</i> (2016)	Turkey; outpatient adolescence clinic in tertiary referral hospital	Not stated	Normal menstrual cycles, with no evidence of hyperandrogenism and normal ovarian morphology on pelvic ultrasonography with a Ferriman–Gallwey score (FGS) <8	The BMI and WHR were assessed by a single investigator for all subjects		No subjects were treated with corticosteroids, or any other med- ication for at least 3 months be- fore study participation statins aspirin, oral contraceptives
Dadachanji et <i>al.</i> (2015)	India; Infertility and Endocrinology outpatient clinic	General population	Age-matched regularly menstruat- ing women with absence of any clinical and/or biochemical signs of hyperandrogenaemia and having normal ovaries on ultrasound im- aging, with the same ethnic background			Participants who had taken any medication that would alter hor- monal parameters or lipid and car- bohydrate metabolism were excluded
De Medeiros et al. (2014)	Brazil; outpatient reproductive and endocrine clinic in a University Hospital	Same clinic as PCOS	Tubal or male cause of infertility and lack of PCOS	Weighed on an electronic scale, and their height was measured us- ing a Harpender stadiometer (Holtain Limited, Crymych, Dyfed, UK). The waist was measured at the midway point between the lower rib margin and the iliac crest, and the hip was measured from the widest circumference over the great trochanters		
de Zegher et al. (2017)	Spain/Germany; University Hospitals in Barcelona, Spain and Datteln, Germany	Recruited from nearby schools and from hospital staff	Healthy, regular menses and had an ethnic background similar to those of PCOS	Height and weight at PCOS diag- nosis were retrieved from medical records		
Fan et <i>a</i> l. (2012)	China; outpatient reproductive endocrinology department at University Hospital	Same clinic as PCOS	Infertile women due to salpingian obstruction or the husband's infer- tility. All were clinically healthy women who had regular men- strual cycles (<35 days), exhibited normal circulating androgen con- centrations and the absence of ob- vious acne or hirsutism on physical examination or polycystic ovaries as determined by ultrasound	Waist circumference was obtained as the smallest circumference at the level of the umbilicus. Hip cir- cumference was obtained as the widest circumference at the level of the buttocks and waist-to-hip ratio was calculated to assess body-fat distribution. Body weight in light clothing and barefoot height were measured		
Gümüş et al. (2015)	Turkey; outpatient adolescence department	Same clinic as PCOS	Patients without PCOS who had been admitted for vaginal and uri- nary system infections			
Gourgari <i>et al.</i> (2015)	USA: Paediatric Endocrine Division of Infants and Children's Hospital and also from other physicians	Database at Healthy Volunteer Office of the National Institutes of Health + local advertisement	18–29 years old with normal men- strual function and without evi- dence of PCOS were eligible; they had to be off oral contraceptive pills or any other medications that alter steroidogenesis for at least I month prior to participating	The waist-to-hip was measured by our dietitian in all participants. Waist circumference was mea- sured at the minimum circumfer- ence between the iliac crest and the rib cage. Hip circumference was measured at the maximum protuberance of the buttocks		

Author (year)	Country, PCOS recruitment source	Control recruitment source	Control description	Measurement of height, weight, waist, and/or waist– hip ratio	Diet and physical activity	Medications
Haldar et <i>al.</i> (2018)	India; Outpatient Department of Obstetrics and Gynaecology	Same clinic as PCOS	Age-matched healthy female vol- unteers with regular menstrual cycles (26–34 days), normal ovar- ian morphology, and normal total testosterone levels			
Hart e <i>t al</i> . (2011	Australia; Western Australian Pregnancy Cohort (Raine) Study	Same cohort as PCOS				
Hickey et al. (2011)	Australia; Western Australian Pregnancy Cohort (Raine) Study	Same cohort as PCOS				Not taking any sex steroid hor- mones or other medication likely to interfere with pituitary, ovarian or endometrial function. Participants
Hudecova et al. (2011)	Sweden; out-patient register at University Hospital	Population registers	Residing in same county and born during the same month as the index patients. Healthy control status was assured by the absence of polycystic ovaries on transvaginal ultrasound. Furthermore, all control subjects de- nied a prior history of oligomenor- rhoea or amenorrhoea (lasting more than 3 months)			
Kaewnin et al. (2018)	Thailand; University students in Bangkok	Same group as PCOS				
Kim et al. (2019)	Korea; PCOS speciality clinic at University Hospital	Healthcare centre in the same University Hospital	No specific age criteria. They had regular (21–35 days) menstrual cycles, a modified Ferriman-Gallwey score < 6, and no polycystic ovary morphology on pelvic ultra- sound examination. They were taking no medications and did not have physi- cian-diagnosed diabetes			For patients on oral contracep- tives at their evaluation, medica- tion was discontinued for a minimum of I month before bloo collection
Koivuaho et al. (2019)	Finland; Northern Finland Birth Cohort 1966	Same cohort as PCOS	Women without any PCOS symp- toms at age 31 and without PCOS diagnosis by age 46			
Kyrkou et <i>al.</i> (2016)	Greece; outpatient clinic at Department of Gynaecology and Obstetrics	Healthcare professionals	Healthy volunteer females (stu- dents, medical and paramedical students, nurses, and doctors), who had normal ovulatory cycles (26–35 days) and no sign of hyperandrogenism			Treatment with compounds af- fecting sex hormones (oral contra ceptives) or other medications within the previous 6 months served as exclusion criteria
Li et al. (2013)	China; outpatient reproductive clinic	Not stated	Regular menstrual cycle (26– 35 days) and normal ovarian mor- phology. Total testosterone and	Waist circumference was mea- sured midway between the lowest rib and the iliac crest. Hip circum-		No hormonal therapy for at least 3 months prior to the test. Medication history were collected

modified Ferriman-Gallwey score

were evaluated for exclusion of

hyperandrogenism

ference was the longest measure-

ment of hip

3 months prior to the test. Medication history were collected to exclude those who have had weight or glucose affecting measures like metformin or oral hypoglycaemic agents

Author (year)	Country, PCOS recruitment source	Control recruitment source	Control description	Measurement of height, weight, waist, and/or waist– hip ratio	Diet and physical activity	Medications
Nambiar et al. (2016)	India; women's health and fertility outpatient clinic	Same clinic as PCOS	Not stated			
Oztas et al. (2016)	Turkey; outpatient reproductive endocrinology clinic	Not stated	Healthy age-matched adolescents were also recruited as control group. All adolescents were fur- ther evaluated by an experienced, single paediatrician in order to ex- clude any possible concomitant endocrinological and other sys- temic diseases. All			Exclusion criteria included medica- tions known to alter insulin secre- tion or action
Pepene (2012)	Romania; not stated	Not stated	Controls had no evidence of clini- cal and/or biochemical androgen excess. In addition, exclusion cri- teria were also applied to the con- trol group			Exclusion based on current or pre- vious use (within 6 months) of oral contraceptives, antiandrogens, in- fertility medication or drugs known to affect carbohydrate- lipid metabolism
Petta et al. (2017)	Italy; PCOS outpatient clinic	General Practitioner referral	They were part of an ongoing project aimed at assessing cardio- vascular risk and liver damage in the general population, according to presence or absence of fatty liver. All women enrolled as con- trols had available an abdominal and pelvic ultrasound performed during the last year, aimed at see- ing both liver and ovarian morphology	Waist circumference (WC) was measured at the midpoint be- tween the lower border of the rib cage and the iliac crest		Excluded women treated with clo- miphene citrate, oral contracep- tives, antiandrogens, drugs to control their appetite or insulin- sensitizing drugs during the 6 months before the examination
Rahmanpour et al. (2012)	Iran; randomly selected PCOS members from previous study	Same study as PCOS	Randomly selected adolescents from normal adolescents of previ- ous study	Waist circumference was mea- sured midway between the lowest rib and the iliac crest with the sub- ject standing at the end of gentle expiration, and hip circumference at the greater trochanters. Weight was measured in kilograms and height was measured to the near- est 0.5 cm		The exclusion criteria were, use of any medications known to affect sex hormone, glucose or lipid me- tabolism for at least a month and oral contraceptives for 3 months before entering the study
Ramos and Spritzer (2015)	Brazil; advertisement via local media	Same as PCOS				No participant received any drugs known to interfere with hormone levels (such as oral contraceptive pills, antiandrogens, metformin, fibrates, or statins) for at least 3 months before the study

(continued)

Supplementary Table SV Continued							
Author (year)	Country, PCOS recruitment source	Control recruitment source	Control description	Measurement of height, weight, waist, and/or waist- hip ratio	Diet and physical activity	Medications	
Roe et al. (2013)	USA; Outpatient Gynaecology clinic	Not stated					
Santos <i>et al.</i> (2018)	Brazil; advertisement in local media	Same as PCOS				Exclusion criteria included having used drugs known to interfere with hormone levels (such as ora contraceptive pills, antiandrogens progestins, metformin, fibrates, o statins) for 3 or more months be- fore the study	
Shi et <i>al.</i> (2013)	China; outpatient reproductive clinic	Same clinic as PCOS	Regular ovulatory menstrual cycles (26–32 days), normal androgen levels and ovary morphology, who received IVF treatment because of fallopian tube occlusion, and were in general good health				
Wang et <i>al.</i> (2019)	China; outpatient clinic at Department of Obstetrics and Gynaecology	Outpatient infertility clinic					
Woo et al. (2012)	South Korea; Gynaecology outpa- tient clinic at Hospital	Advertisements at the same hospital	Control subjects were women with regular menstrual cycles (25- 35 days) and had no evidence of hirsutism, acne, alopecia or endo- crine dysfunction, and no polycys- tic ovary (<12 follicles with size of 2–9 mm/ovary). Exclusion			None of the subjects had taken any medications for at least 6 months prior to the study, includ- ing oral contraceptives, glucocorti coids, ovulation induction agents, anti-obesity drugs, and estrogenic anti-androgenic, or anti-hyperten- sive medication	
Wu et <i>a</i> l. (2018)	China; Outpatient Obstetrics and Gynaecology Department	Same clinic as PCOS					
			Studies from Previous System	atic Review			
Adali et <i>al.</i> (2008)	Turkey; Outpatients clinics of Department of Gynaecology and Obstetrics at University	Same clinic as PCOS	Age-matched, similar SES			No oral contraceptives, glucocor- ticoids, antiandrogens, insulin sen- sitizers, or psychiatric medications for 6 months prior	
Al-Ojaimi (2006)	Bahrain, tertiary referral teaching hospital	Same department same time period	Normal menses, no hyperandrogenism				
Altieri et al. (2010)	Italy, academic hospital	Same group as PCOS	Eumenorrhoeic, no signs of hyper- androgenism, and normal ovarian morphology				
Amato et al. (2008)	Italy, outpatients clinic	Same group as PCOS	Suspected of PCOS			No clomiphene citrate, oral con- traceptives, anti-androgens, drugs to control their appetite, or insuli sensitizing drugs (metformin, pio- glitazone, rosiglitazone) 6 months prior	

Supplementary Table SV Continued							
Author (year)	Country, PCOS recruitment source	Control recruitment source	Control description	Measurement of height, weight, waist, and/or waist– hip ratio	Diet and physical activity	Medications	
Azziz et al. (2004b)	USA, reproductive endocrinology clinic	Same group as PCOS					
Bernasconi et al. (1996)	Italy, endocrinology clinic	Not stated	Nonhirsute, eumenorrhoeic, age- matched			No medications for hirsutism for 3 months prior	
Beydoun <i>et al.</i> (2009)	USA, fertility treatment centre	Same time period and fertility treatment centre as PCOS	Age- and period-matched non PCOS women				
Carmina et al. (2006)	Italy, two endocrinology depart- ments at university	Same group as PCOS-re- ferred for hyperandrogenism	Idiopathic hirsutism and idiopathic hyperandrogenism; normal ovula- tory cycles and normal ovaries on ultrasound			No medications for 3 months prior	
Chae et al. (2008)	South Korea, Department of Obstetrics and Gynaecology at Seoul National University Hospital	Healthcare centre in our hospital as a part of group checkup for work or an association or an individ- ual need for annual com- prehensive medical checkup with no specific	No hirsutism, acne or male-type alopecia, all had regular menstrual cycles, none had PCO, none had any of the Rotterdam criteria			No medication affecting gonado- trophin status for 6 months prior	
Chen et <i>al.</i> (2010)	Taiwan, reproductive endocrinol- ogy clinic	health problems Consecutive series (<35 years old) receiving voluntary annual medical check-up at the same hospital as PCOS	Matched by 3-year age strata			No use of oral contraceptives within 6 months of enrolment, or the use of medications known to affect the hypothalamic-pituitary- ovarian axis, such as anti-andro- gens, ovulation induction agents, antidiabetic medications, anti-obe- sity medications, or glucocorticoids	
Cheung et al. (2008)	Hong Kong, endocrinology and in- fertility clinics at university hospital	61 from the community and the remaining were from same clinic as PCOS, mostly presented with tubal infertility	Regular menstrual cycles, no hir- sutism/acne, or ultrasound fea- tures of PCO	Narrowest measurement midway between the top of the iliac crest and the lower rib margin, whereas the hip circumference was taken as the widest measurement at the level of the greater trochanters		No use of medications known to affect steroid or glucose metabo- lism in past 3 months	
Chhabra and Venkatraman (2010)	India, gynaecological outpatient unit	From the same group	Menstrual dysfunction				
Ciampelli et al. (2000)	Italy, referred to authors' hospital	Not stated	Normo-ovulatory			No medication known to affect plasma sex steroid levels for at least 3 months prior	
Dokras et al. (2005)	USA, endocrinology clinic	Randomly selected from women who were seen for an annual examination by two healthcare pro- viders in the gynaecology	Regular menses and an absence of hirsutism			3/129 using cholesterol-lowering medications	

Author (year)	Country, PCOS recruitment source	Control recruitment source	Control description	Measurement of height, weight, waist, and/or waist- hip ratio	Diet and physical activity	Medications
		clinic over the same time period as the patients with PCOS				
Echiburú et <i>al.</i> (2008)	Chile, endocrinology unit of university	Community centres of the same geographical area as the patients and had the same socioeco- nomic level	Regular 28- to 32-day menstrual cycles, absence of hirsutism and other manifestations of hyperan- drogenism, and absence of galac- torrhoea and/or thyroid dysfunction	Height-nearest 0.1 cm using wall- amounted stadiometer; weight- nearest 0.1 kg using a hospital bal- ance beam scale		
Economou et al. (2009)	Greece, PCOS-endocrine unit at hospital	Not stated	Normo-androgenaemic and regu- larly ovulating women		Excluded if they have a history of alcohol intake of higher than 20 g per day	No oral contraceptives, insulin sensitizers or any medication in- terfering with metabolic or hor- monal measurements in 3 months prior
Ferk et <i>al.</i> (2007	Slovenia, Department of Obstetrics and Gynaecology at university	Authors' clinic	Age-matched, healthy with proven fertility (seen in clinic for normal pregnancy), no menstrual cycle ir- regularities, with no clinical or bio- chemical hyperandrogenism and without PCO. They also had no history of endocrinological or auto- immune disorders and no surgery to the pelvic region			
Glueck <i>et al.</i> (2003)	USA, possibly outpatients of cho- lesterol centre			Without shoes or over-clothes		No hormones, corticosteroids, or anticoagulants
Glueck et al. (2003)	USA, possibly outpatients of cho- lesterol centre	Same group as PCOS, hospital personnel	Idiopathic intracranial hypertensive			J
Glueck et al. (2005a)	USA, patients of cholesterol centre	NHANES I and commu- nity obstetrics practice study	Same age group	Clothed weight		No androgens, oestrogen-proges- tins, oestrogen-androgens, or drugs known to effect endogenous sec hormones or lipoprotein me- tabolism in 2 months prior
Glueck et al. (2005b)	USA, possibly outpatients of cho- lesterol centre	Same group as PCOS	Idiopathic intracranial hypertensive			
Glueck et al. (2006)	USA, adolescents from Ohio, Kentucky, West Virginia, Indiana, Michigan, and included all at cho- lesterol centre	NHLBI Growth and Health Study	Normal, regularly cycling			No oestrogen-progestin oral contraceptives
Glueck et al. (2008)	USA, patients of cholesterol centre				Encouraged to stay on low-carbohydrate high- protein diet	

(continued)

Author (year)	Country, PCOS recruitment	Control recruitment	Control description	Measurement of height,	Diet and physical	Medications
	source	source		weight, waist, and/or waist– hip ratio	activity	
Glueck <i>et al.</i> (2009)	USA, patients of cholesterol centre	Princeton follow-up study	Healthy free-living population, reg- ular menses	Light indoor clothing without shoes, two measurements, if dif- fered by more than 0.5 cm for ht or 0.3 kg for wt, third measure- ment will be done		
Hahn et <i>a</i> l. (2005)	Germany, outpatient clinics	Health-screening pro- gramme for employees instituted at the University of Duisburg- Essen Medical Centre and by public advertisement	No NIH-PCOS or other medical conditions			No prescription medication ex- cept allergy medications and occa sional pain medications for at leas 3 months
Hahn et <i>al.</i> (2007)	Germany, outpatient clinics	Screening programme for employees of the University of Duisburg- Essen	Matched in sociodemographic var- iables, including family status, edu- cation, and employment. No PCOS (NIH) or any known medi- cal condition			No medication known to affect carbohydrate and lipid metabolisi or endocrine parameters for at least 3 months
Liou et al. (2009)	Taiwan, reproductive endocrinol- ogy clinic at Taipei Medical University	Same group as PCOS	No more than one of the follow- ing three PCOS components: (i) PCOM, (ii) Oligo-An, and (iii) HA			
Mukherjee et al. (2009)	India, infertility clinic and endocri- nology clinic	General population	Age-matched, regular menstrual cycles and no clinical and/or bio- chemical signs of hyperandroge- naemia or polycystic ovaries			No medication known to affect carbohydrate and lipid metabolisi or endocrine parameters for 3 months prior
Nácul et <i>al.</i> (2007)	Brazil, consulting patients (from where?)	Same group as PCOS	Age-matched women with regular, ovulatory cycles, normal androgen levels, and idiopathic hirsutism			No drugs known to interfere with hormonal levels for 3 months prior; no heparin or aspirin withir 15 days of test
Pasquali et <i>al.</i> (1993)	Italy, location not stated	Those who attended the institute for evaluation and treatment of obesity or for general health checkup, and hospital staff	Normal menses, no hirsutism, or other signs of androgenization	Without shoes to the nearest 0.5 cm and body weight without clothes		
Patel <i>et al.</i> (2008)	USA, endocrinology clinic	Randomly selected from among female patients with regular menses by the same endocrinologist in the same time period	Regular menses recruited at same time period by the same endocrinologist			No lipid powering agents or anti- hypertensive agents (except spironolactone)
Shroff et <i>al.</i> (2007)	USA, reproductive endocrinology clinic	Seen for annual examina- tion at gynaecology clinic during same time period	Regular menses, no hirsutism			
Spranger et al. (2004)	Germany, location not stated	Not stated	No menstrual disorders or signs of hyperandrogenism			No medication

Author (year)	Country, PCOS recruitment source	Control recruitment source	Control description	Measurement of height, weight, waist, and/or waist– hip ratio	Diet and physical activity	Medications
Vrbikova et al. (2007)	Czech Republic, outpatient ter- tiary endocrine department	Via advertisement	All lacked symptoms of hyperan- drogenism, had a regular men- strual cycle (21–35 days), and had androgen levels within the refer- ence range	To nearest 0.1 kg and height to nearest cm		
Wang et al. (2009)	China, reproductive centre clinic	Same geographic area, recruited in the same pe- riod and evaluated consecutively	Age-matched, normal ovulatory menstrual cycles, absence of hir- sutism and other manifestations of hyperandrogenism, and absence of sonographic signs of PCOS. None of them had sign of galac- torrhoea and thyroid dysfunction or personal or family history of diabetes			No hormonal preparations, in- cluding oral contraceptives for at least 3 weeks prior

Table design and previous SR contents taken from 2012 SR by Lim et al. (2012) (Human Reproduction Update).